Announcements Trials

Browse Landscape

Phase

Phase 2 4 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 24 Lymphoma, Non-Hodgkin 17 Lymphoma, Follicular 14 Lymphoma, Mantle-Cell 9 Lymphoma 6 Lymphoma, B-Cell, Marginal Zone 5 Recurrence 3 Neoplasms 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, B-Cell 2 Leukemia 2 Hematologic Diseases 2 Waldenstrom Macroglobulinemia 1 Tumor Lysis Syndrome 1 Multiple Myeloma 1 Lymphoma, T-Cell, Peripheral 1 Leukemia, B-Cell 1 Immunoblastic Lymphadenopathy 1 Hodgkin Disease 1 Chromosome 17 deletion 1

Interventions

ofatumumab 3 venetoclax 2 pirtobrutinib 2 obinutuzumab 2 ibrutinib 2 Chlorambucil 2 acalabrutinib 1 Tablets 1 Observation 1 Cholecalciferol 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Leukemia, B-Cell × Bendamustine Hydrochloride × Clear all

NCT01678430 2012-10-15

RIAltO

University of Liverpool

Phase 3 Unknown

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡